TAS2Rs, particularly in enteroendocrine cells, are involved in the release of GLP-1
[1] [3] Key risk factors for developing hypotension on GLP-1 therapy include: Concurrent use of antihypertensive medications, especially diuretics, ACE inhibitors, or ARBs Concomitant use of SGLT2 inhibitors, which can cause osmotic diuresis and volume depletion Baseline blood pressure in the low-normal range (systolic 90-110 mmHg) Advanced age (65 years and older) Autonomic dysfunction or diabetic neuropathy Rapid or substantial weight loss Inadequate fluid intake or gastrointestinal side effects causing dehydration Concomitant use of other medications that lower blood pressure Patients with type 1 diabetes using off-label GLP-1 therapy or those with longstanding type 2 diabetes and cardiovascular autonomic neuropathy may be at higher risk for orthostatic hypotension
It typically remains stable for about 1014 days, but always refer to your providers guidance for the exact duration
Nearly one-third (32%) had kept their weight loss efforts to themselves at work, and only 1 in 10 said they would disclose their GLP-1 use to a new employer
Vi nhng ai ang tm hiu thm v vin ung trng da glutathione t cc thng hiu khc nhau, hy lun p dng quy trnh 3 bc trn bo v quyn li ca chnh mnh